Tablets with hardness and abrasion resistance can be manufactured: OSDrC technology and contract formulation development.
Introducing the improvement of moldability using OSDrC technology! Even active ingredients with molding defects can be tabletized.
The "OSDrC" technology allows for precise and flexible control of the inner core due to its variable double-structure tablet design, enabling not only the production of higher quality core tablets than conventional methods but also the development of various new dosage forms. By localizing the active ingredient in the inner core and using a highly moldable powder for the outer layer, it is possible to create tablets even from active ingredients that have poor moldability. 【Features】 ■ The increase in tablet size can be minimized even for OD tablets, which tend to have a larger amount of powder. ■ The hardness and disintegration of the tablets can be adjusted according to the intended purpose. ■ It is possible to combine with other OSDrC technologies, such as OD tablets that do not expose the inner core even when split. ◎●◎ Sample Presentation ◎●◎ We will send samples made using OSDrC technology to those who request them. Please indicate the quantity in the inquiry form. * Data comparing the wear degree of OSDrC tablets made with OSDrC technology and tablets physically mixed with active ingredients that have poor moldability can be viewed by downloading the PDF below. * For more details about OSDrC technology, please refer to the OSDrC main brochure or feel free to contact us.
Inquire About This Product
basic information
Price range
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
catalog（2）
Download All Catalogs
Company information
Sanwa Chemical Research Institute, as a member of the Suzuken Group focused on health creation, provides services aimed at improving the quality of life (QOL) for people who wish for better health, centered around its two main businesses: "pharmaceuticals" and "diagnostic drugs." In the "pharmaceuticals business," we are steadily building a track record with a focus on new drugs in the areas of diabetes and kidney/dialysis-related fields. In the "diagnostic drugs business," we are continuously developing and launching self-blood glucose meters, sensors, and diagnostic drugs for infectious diseases. Furthermore, by adding two more businesses— the "OSDrC (Osudrack) business" utilizing innovative formulation technology and the "contract manufacturing business" with advanced quality control systems— Sanwa Chemical Research Institute continues to evolve further.